Search PubMed⌕ Search

Biomedical subjects

M Schachter

Publications and source records attributed to M Schachter.

At least 181 records · Page 10Linked to original sources
PubMed1981

Lisuride in parkinsonism.

Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.

Administration, Oral↗
PubMed1981

[Not Available].

Explore the source record for details and available documents.

Austria↗
PubMed1980

The role of D-1 and D-2 receptors.

Dopamine receptors in intracerebral motor and endocrine systems have been divided into two main types, D-1 and D-2, dependent on the presence or absence of adenylate cyclase linkage. Here we have investigated a number of dopamine agonist and antagonist drugs in man that have different actions on D-1 and D-2 receptors in animals. Motor and endocrine effects in parkinsonian subjects seem to depend on drug interaction with D-2, but not D-1, receptors. These results may have important implications for the design of anti-parkinsonian and antipsychotic agents.

Adenylyl Cyclases↗
PubMed1980

Lisuride in the treatment of Parkinsonism.

Lisuride 1.2-4.8 mg daily was given to 10 patients with severe Parkinsonism for up to 9 months. All had been taking bromocriptine and eight had been taking levodopa combined with carbidopa. Total replacement of bromocriptine by lisuride was achieved in every case, but partial or total levodopa replacement was possible only in five patients. Lisuride 1 mg has approximately the same antiparkinsonian activity as bromocriptine 15 mg or levodopa 250-500 mg combined with carbidopa, but the duration of action of each dose is short, and gastro-intestinal and neuropsychiatric side effects are common. However, lisuride i.v. may be of considerable value in the emergency treatment of severe Parkinsonism.

Administration, Oral↗
PubMed1980

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

Fluctuations in response to levodopa are a common and serious complication of long-term levodopa therapy. It may be possible to prolong the effect of each dose of levodopa by retarding the breakdown of dopamine. The selective monoamine oxidase type B inhibitor deprenyl, which is extensively metabolised to amphetamine and methamphetamine, has this effect as well as possible actions on dopamine release and re-uptake. In a double-blind crossover trial against placebo, deprenyl prolonged the action of levodopa and produced an objective improvement in mobility in five of 10 patients with dose-related response swings, and a subjective improvement in a further four patients. In another group of seven patients with random fluctuations in symptoms, only two noted subjective improvement, and there was an apparent increase in the severity of response swings in five patients. Deprenyl exacerbated dyskinesias, but had no serious side-effects. We conclude that deprenyl is unlikely to benefit patients with random response swings, and may cause deterioration in such cases. However, it may be a useful adjuvant in the management of dose-related response fluctuations in patients already on optional levodopa therapy.

Aged↗
PubMed1980

Fluvoxamine and clomipramine in the treatment of cataplexy.

Fluvoxamine 25-200 mg daily and clomipramine 25-200 mg daily were given for separate three week periods to 18 subjects with narcolepsy and cataplexy. Both drugs improved cataplexy but not narcolepsy. Fluvoxamine was less active than clomipramine, but both drugs abolished cataplexy in individual subjects. Gastrointestinal side effects prevented treatment with fluvoxamine in five subjects. All patients completed the clomipramine phase of the trial, but two men complained of delayed ejaculation. Fluvoxamine is a more potent inhibitor of 5-hydroxytryptamine (5-HT) reuptake in some systems, but not in others. It is therefore uncertain whether the greater anticataplectic effect of clomipramine is due to a greater inhibition of 5-HT reuptake or to other mechanisms.

Adult↗
PubMed1980

Localization of kallikrein in submandibular gland of cat, guinea pig, dog, and man by the immunoperoxidase method.

The sensitive immunoperoxidase method was used to localize kallikrein in the submandibular gland of the cat, guinea pig, dog, and man. In every instance, kallikrein was localized in the apical region of duct cells, a location suggesting its secretion into the duct system. There was no evidence of the enzyme in other cells or interstitial tissue in the gland. The major source of submandibular gland kallikrein, therefore, must be of ductal origin. The classification of kallikreins with the widely distributed group of serine proteases is discussed, as is their possible significance in regulating physiological processes by specific and limited proteolysis.

Animals↗
PubMed1980

[Not Available].

Explore the source record for details and available documents.

France↗
PubMed1980

[The adopted child and his problems. Pedo-psychiatric point of view].

After a survey of the recent pedopsychiatric literature concerning the difficulties exhibited by young adoptees, we describe our own experience with 35 adopted children. The subjects were divided in two groups: a) the first group of 26 cases (74%) concerning clinical disturbances with no evident relation to the situation derived by the adoption; b) the second group of 9 cases (26%) concerning: 1. four cases ou rebellious behaviour against the adopters et 2. fives cases of camouflaged rejection of the adoptees by their adopters. These 9 cases are given with details; the characteristics of the other 26 cases are summarized. Our pedopsychiatric experience has shown that adoption was a failure in 26% of the cases related in the present study.

Adolescent↗
PubMed1980

[Psychodynamics of "masked" responses on the Rorschach test in adults].

Despite of their importance, "mask" answers to the Rorschach test, suspected but not studied by H. Rorshach, retained the attention of R. Kuhn (1944) in his classical book. The present study concerns 43 adults of both sexes, from a total of 605 adults (6.9%) examined for various nevrotic disturbances, who gave, at least, one single "mask" response to this test. Following a detailed analysis of the characteristics of their rorschachogrammes, the author underlines that these relatively rare responses exhibit: a) difficulties or conflicts in relation with problems of "being seen", "being judged", "unmasked" by others, or b) in relation with difficulties arising from inferiority feelings and complexes, ambiguities or dissimulations.

Adult↗